Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. CRC, however, is potentially preventable, and several strategies may be employed to decrease the…
Assessment of patient-reported outcomes (PROs) provides important information to assist with clinical decision making. There has been significant progress in the field of PROs over the past 2 decades with…
Melanoma is the most aggressive form of skin cancer. Unfortunately, despite recent improvements for some solid tumors, the prevalence and mortality of melanoma continue to increase. The identification of activating…
This article reviews the best evidence available to guide the follow-up of patients with melanoma, focusing on incidence of, and detection of, melanoma recurrence, frequency of follow-up visits, yield of, laboratory…
The incidence of melanoma has been increasing worldwide. A relationship between melanoma and the immune system was established years ago. Modulating the immune system in the management of different stages…
Although the conventional paradigm for treating metastatic melanoma relies on systemic therapies, a surgical approach should be strongly considered in selected patients. A surgical approach may not be appropriate for…
Radiation therapy plays an integral role in the management of melanoma. Radiation therapy is infrequently needed for the treatment of the primary site, but there are occasions when it is…
For in-transit melanoma confined to the extremities, regional chemotherapy in the form of hyperthermic isolated limb perfusion and isolated limb infusion are effective treatment modalities carrying superior response rates to…
Adjuvant therapy is commonly used in melanoma because recurrence after surgery usually results in the patient’s eventual death. Surgeons have a profound influence on patients’ decisions regarding adjuvant therapy, beginning…
The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy was introduced 20 years ago as an important advance in the management of patients with stage I and II…
